Articles Mentioning Biotechnology Stocks

Results 1 - 10 of 390 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology

Investing | May 21, 2015

Johnson & Johnson Just Stepped Up Its Hepatitis C Game

Johnson & Johnson has inked a licensing deal with Achillion Pharmaceuticals that could threaten Gilead Sciences market share in hepatitis C. Should Gilead investors worry?

Investing | May 10, 2015

Investors Just Doubled Their Money on This Stock

Alexion is paying $8.4 billion to buy Synageva, a company without any sales, so in today's episode we're digging into this deal to see what it may mean to biotech investors.

Investing | May 05, 2015

Is This Why the Street Keeps Doubting Gilead Sciences, Inc.?

Gilead Sciences looks like a screaming buy right now based on its fundamentals. But the Street apparently doesn't think so. Here's why.

Investing | April 27, 2015

Biotech Bubble Bursting? 3 Stocks I Want to Buy

Celgene Corporation, Amgen Inc., and Gilead Sciences Inc. may be good biotech stocks to buy on a sell-off.

Investing | April 27, 2015

The Internet of Things is About to Solve Biotech's Oldest Problem

The field where the Internet of Things is likely to have the biggest impact is often the field no one associates with it: biotech.

Investing | April 19, 2015

3 Stocks That Could Double Your Money

These three companies have the potential to double their share price from current levels. Here's why.

Investing | April 16, 2015

The Best Stock to Invest in Hep C

In the multibillion-dollar market for hepatitis C, this company stands above the crowd.

Investing | April 15, 2015

3 Promising Healthcare Stocks Under $10

Healthcare stocks with plenty of potential -- and low share prices

Investing | April 08, 2015

Should AbbVie, Inc. Buy Acadia Pharmaceuticals to Help Fight Parkinson's Disease?

AbbVie is reportedly still interested in acquiring additional assets to help it over the Humira patent cliff hump. Would Acadia Pharmaceuticals be a good match for this big pharma?

Investing | April 05, 2015

Can This Pharma Go From Good to Great?

Will Actavis' $66 billion merger with Allergan catapult this company from good to great? Or could a hidden risk derail this global powerhouse?

Results 1 - 10 of 390 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology